Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I dose-escalation study of ValloVax for the treatment of non-small stage lung cancer

Trial Profile

A Phase I dose-escalation study of ValloVax for the treatment of non-small stage lung cancer

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 20 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Placental-derived cell therapy-(ValloVax) (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Batu Biologics
  • Most Recent Events

    • 20 Aug 2018 According to a Batu Biologics media release, this trial is expected to initiate in late 2018.
    • 07 Nov 2017 According to a Batu Biologics media release, ValloVax, has received an Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) allowing the company to proceed with phase I clinical trials.
    • 26 Jan 2016 According to a Batu Biologics media release, the company expects FDA clearance in the first quarter of 2016 and trial initiation in the second quarter of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top